<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04238299</url>
  </required_header>
  <id_info>
    <org_study_id>DHRD/2018/100</org_study_id>
    <secondary_id>271043</secondary_id>
    <nct_id>NCT04238299</nct_id>
  </id_info>
  <brief_title>Application of Functional Renal MRI to Improve Assessment of Chronic Kidney Disease</brief_title>
  <acronym>AFiRM</acronym>
  <official_title>Application of Functional Renal MRI to Improve Assessment of Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospitals of Derby and Burton NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Nottingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Queen Elizabeth University Hospital Glasgow</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Infirmary of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Newcastle University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Newcastle-upon-Tyne Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Leeds</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Leeds Teaching Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sheffield Teaching Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Sheffield</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Salford Royal NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Cambridge</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cambridge University Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospitals of Derby and Burton NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Research question: Can multiparametric renal Magnetic Resonance Imaging (MRI) provide
      structural and functional assessment of the kidneys to deliver prognostic information and
      guide treatment options in chronic kidney disease (CKD)?

      Aims and objectives:

        1. To establish a multiparametric renal MRI protocol in CKD cohorts.

        2. To use multiparametric MRI to characterise people with and without CKD progression.

        3. To compare multiparametric renal MRI with 'gold-standard' renal biopsy to determine
           pathological processes of CKD progression that are detectable by MRI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will have three stages.

      Stage 1: 45 people with CKD from nine UKRIN centres will undergo multiparametric MRI to test
      patient tolerance, data completeness and central data collection processes.

      Stage 2: A multicentre, prospective cohort study of 450 people with CKD, collecting
      multiparametric renal MRI at baseline and 2 years. Long-term outcomes will be determined with
      efficient tracking of kidney failure events via the UK Renal Registry at 5 and 10 years.

      Stage 3: A mechanistic sub-study of 45 patients (from Stage 2) who have had a routine renal
      biopsy. Detailed comparisons will be made between multiparametric MRI and histopathological
      changes. Tissue blocks will undergo quantitative analysis of fibrosis, capillary density and
      inflammation using immunohistochemistry techniques.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2033</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2027</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>CKD progression</measure>
    <time_frame>10 years</time_frame>
    <description>kidney failure (doubling of serum creatinine, eGFR&lt;15ml/min or RRT) OR a 40% decline in eGFR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Kidney failure events</measure>
    <time_frame>10 years</time_frame>
    <description>Doubling of serum creatinine, eGFR&lt;15ml/min or RRT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>40% decline in eGFR from baseline</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>eGFR trajectory</measure>
    <time_frame>2 years</time_frame>
    <description>(ml/min/yr)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AKI events</measure>
    <time_frame>4 years</time_frame>
    <description>AKI as per KDIGO serum creatinine criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular events</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Renal MRI measures</measure>
    <time_frame>2 years</time_frame>
    <description>As detailed in interventions section</description>
  </other_outcome>
  <other_outcome>
    <measure>Renal histology measures</measure>
    <time_frame>Baseline</time_frame>
    <description>Glomerulosclerosis score, extent of interstitial fibrosis, inflammation, peritubular capillary density, collagen accumulation, inflammatory cell subtypes</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Chronic Kidney Diseases</condition>
  <arm_group>
    <arm_group_label>Main study cohort</arm_group_label>
    <description>Patients with CKD recruited from specialist nephrology clinics</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Multiparametric renal MRI</intervention_name>
    <description>Localiser scans; Kidney volume; Longitudinal (T1) relaxation time mapping; Diffusion weighted imaging (DWI); Phase Contrast MRI; Arterial spin labelling (ASL); Blood Oxygen Level Dependent (BOLD) mapping</description>
    <arm_group_label>Main study cohort</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Stored samples: plasma, serum, urine and DNA at study entry Multiparametric renal MRI
      measures at study entry and after 2 years of follow up
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Chronic kidney disease
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Age 18-75 years

          -  CKD category G3-4 or CKD category G1-2 with overt albuminuria (urine ACR&gt;30mg/mmol)

          -  Capable of giving informed consent

        Exclusion Criteria

          -  Autosomal dominant polycystic kidney disease (ADPKD)

          -  Glomerulonephritis (GN) actively receiving immunosuppression, or within the preceding
             90 days.

          -  Multiple myeloma (MM)

          -  Acute Kidney Injury (AKI) within the preceding 90 days

          -  Solid organ transplant

          -  Known single kidney

          -  Contraindications to MRI (e.g. permanent pacemaker, metallic foreign bodies,
             claustrophobia etc.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nicholas Selby</last_name>
    <phone>01332 724665</phone>
    <email>nicholas.selby@nottingham.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rachelle Sherman</last_name>
    <phone>01332724736</phone>
    <email>uhdb.afirmstudy@nhs.net</email>
  </overall_contact_backup>
  <link>
    <url>https://www.uhdb.nhs.uk/derby-ctu</url>
    <description>Derby Clinical Trials Support Unit</description>
  </link>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 20, 2020</study_first_submitted>
  <study_first_submitted_qc>January 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2020</study_first_posted>
  <last_update_submitted>February 19, 2020</last_update_submitted>
  <last_update_submitted_qc>February 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

